Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Related Articles by Review for PubMed (Select 16141321)

1.

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5. Epub 2005 Sep 2. Erratum in: Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17882.

2.
3.
4.

TP53 status and response to chemotherapy in breast cancer.

Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thé H.

Pathobiology. 2008;75(2):132-9. doi: 10.1159/000123851. Epub 2008 Jun 10. Review.

PMID:
18544968
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.

Transcription regulation by mutant p53.

Weisz L, Oren M, Rotter V.

Oncogene. 2007 Apr 2;26(15):2202-11. Review.

PMID:
17401429
7.

Microarrays in breast cancer research and clinical practice--the future lies ahead.

Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA.

Endocr Relat Cancer. 2006 Dec;13(4):1017-31. Review.

8.

Current status of prognostic profiling in breast cancer.

Pusztai L.

Oncologist. 2008 Apr;13(4):350-60. doi: 10.1634/theoncologist.2007-0216. Review.

9.
10.
11.

The molecular epidemiology of p53 gene mutations in human breast cancer.

Hartmann A, Blaszyk H, Kovach JS, Sommer SS.

Trends Genet. 1997 Jan;13(1):27-33. Review.

PMID:
9009845
12.

The p53 pathway in breast cancer.

Gasco M, Shami S, Crook T.

Breast Cancer Res. 2002;4(2):70-6. Epub 2002 Feb 12. Review.

13.

TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.

Peller S, Rotter V.

Hum Mutat. 2003 Mar;21(3):277-84. Review.

PMID:
12619113
14.

Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.

Kuderer NM, Lyman GH.

Cancer Invest. 2009 Nov;27(9):885-90. doi: 10.3109/07357900903275142. Review. No abstract available.

15.

Gene profile and response to treatment.

Smeds J, Miller LD, Bjöhle J, Hall P, Klaar S, Liu ET, Pawitan Y, Ploner A, Bergh J.

Ann Oncol. 2005;16 Suppl 2:ii195-202. Review. No abstract available.

16.

The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.

Yang CH, Cristofanilli M.

Future Oncol. 2006 Apr;2(2):247-55. Review.

PMID:
16563093
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk